scholarly journals Diet and Chronic Inflammation

EDIS ◽  
2020 ◽  
Vol 2020 (5) ◽  
Author(s):  
Daniela Rivero-Mendoza ◽  
Wendy J. Dahl
Keyword(s):  
Heart Disease ◽  
Immune System ◽  
Liver Disease ◽  
Chronic Inflammation ◽  
Human Nutrition ◽  
Food Science ◽  
Dietary Choices

Inflammation is your body's response to injury and infection—it's how your immune system helps to protect you from harm. In contrast, chronic inflammation contributes to many diseases, including heart disease, diabetes, and kidney and liver disease. This new 4-page publication of the UF/IFAS Food Science and Human Nutrition Department discusses inflammation and the dietary choices that may help to reduce chronic inflammation. Written by Daniela Rivero-Mendoza and Wendy Dahl.https://edis.ifas.ufl.edu/fs402

scholarly journals Dieta e inflamación crónica

EDIS ◽  
2020 ◽  
Vol 2020 (5) ◽  
Author(s):  
Daniela Rivero-Mendoza ◽  
Wendy J. Dahl
Keyword(s):  
Chronic Inflammation ◽  
Human Nutrition ◽  
Food Science ◽  
Spanish Translation

La inflamación es la respuesta de su cuerpo a las lesiones e infecciones – así es como su sistema inmunológico ayuda a protegerlo de cualquier daño. Por el contrario, la inflamación crónica contribuye a muchas enfermedades, como enfermedades cardíacas, diabetes y enfermedades renales y hepáticas. Esta publicación discute la inflamación y las opciones alimentarias que pueden ayudar a reducir la inflamación crónica.This is the Spanish translation of FSHN20-43, Diet and Chronic Inflammation. Written by Daniela Rivero-Mendoza and Wendy Dahl, translated by Daniela Rivero-Mendoza, and published by the UF/IFAS Food Science and Human Nutrition Department.https://edis.ifas.ufl.edu/fs405

Symptomatology and Clinical Features of Human COVID-19

2022 ◽  
pp. 28-57
Author(s):  
Mohamed Echchakery ◽  
Souad El Mouahid ◽  
Soraia El Baz ◽  
Maryam Mountassir ◽  
Ahmed Taoufik Hakkoum ◽  
...  
Keyword(s):  
Heart Disease ◽  
Immune System ◽  
Liver Disease ◽  
Chest Pain ◽  
Respiratory Syndrome Virus ◽  
Shortness Of Breath ◽  
Massive Obesity ◽  
Difficulty Breathing ◽  
Specific Symptoms ◽  
Fatal Complications

Severe Acute Respiratory Syndrome Virus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was identified at the end of December 2019 in China. Symptoms of COVID-19 can appear after an incubation phase of the virus of 2 to 14 days, the most common being fever, cough, and asthenia. Other specific symptoms may include shortness of breath or difficulty breathing, muscle pain, sore throat, chills, loss of smell or sensation, chest pain, headache, nausea, rash, diarrhea, and vomiting. The severity of these symptoms can be mild or even extreme causing serious damage to several organs, directly and indirectly, namely pulmonary, renal, hepatic, cardiac, digestive, neurological. Some people have only mild symptoms, while others are asymptomatic. Seniors or those at risk for certain chronic diseases, such as massive obesity, diabetes, heart disease, lung disease, kidney disease, immune system abnormalities, and liver disease are more susceptible to COVID-19 and can develop more serious and fatal complications.

The interplay between gut microbiota and the immune system in liver transplant recipients and its role in infections

2021 ◽  
Author(s):  
Giuseppe Ancona ◽  
Laura Alagna ◽  
Andrea Lombardi ◽  
Emanuele Palomba ◽  
Valeria Castelli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune System ◽  
Liver Disease ◽  
Gut Microbiota ◽  
Liver Transplant ◽  
Bacterial Infections ◽  
Multidrug Resistant ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

Liver transplantation (LT) is a life-saving strategy for patients with end-stage liver disease, hepatocellular carcinoma and acute liver failure. LT success can be hampered by several short-term and long-term complications. Among them, bacterial infections, especially due to multidrug-resistant germs, are particularly frequent with a prevalence between 19 and 33% in the first 100 days after transplantation. In the last decades, a number of studies have highlighted how gut microbiota (GM) is involved in several essential functions to ensure the intestinal homeostasis, becoming one of the most important virtual metabolic organs. GM works through different axes with other organs, and the gut-liver axis is among the most relevant and investigated ones. Any alteration or disruption of GM is defined as dysbiosis. Peculiar phenotypes of GM dysbiosis have been associated to several liver conditions and complications, such as chronic hepatitis, fatty liver disease, cirrhosis and hepatocellular carcinoma. Moreover, there is growing evidence of the crucial role of GM in shaping the immune response, both locally and systemically, against pathogens. This paves the way to the manipulation of GM as a therapeutic instrument to modulate the infectious risk and outcome. In this minireview we provide an overview of the current understanding on the interplay between gut microbiota and the immune system in liver transplant recipients and the role of the former in infections.

scholarly journals Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection

2012 ◽  
Vol 6 (2) ◽  
pp. 17 ◽  
Author(s):  
Masachika Senba ◽  
Naoki Mori
Keyword(s):  
Immune Response ◽  
Human Papillomavirus ◽  
Immune System ◽  
Tumor Suppressor ◽  
Chronic Inflammation ◽  
Mhc Class I ◽  
Immune Evasion ◽  
Latency Period ◽  
Class I ◽  
Presentation Pathway

Human papillomavirus (HPV) has developed strategies to escape eradication by innate and adaptive immunity. Immune response evasion has been considered an important aspect of HPV persistence, which is the main contributing factor leading to HPV-related cancers. HPV-induced cancers expressing viral oncogenes E6 and E7 are potentially recognized by the immune system. The major histocompatibility complex (MHC) class I molecules are patrolled by natural killer cells and CD8<sup>+</sup> cytotoxic T lymphocytes, respectively. This system of recognition is a main target for the strategies of immune evasion deployed by viruses. The viral immune evasion proteins constitute useful tools to block defined stages of the MHC class I presentation pathway, and in this way HPV avoids the host immune response. The long latency period from initial infection to persistence signifies that HPV evolves mechanisms to escape the immune response. It has now been established that there are oncogenic mechanisms by which E7 binds to and degrades tumor suppressor Rb, while E6 binds to and inactivates tumor suppressor p53. Therefore, interaction of p53 and pRb proteins can give rise to an increased immortalization and genomic instability. Overexpression of NF-kB in cervical and penile cancers suggests that NF-kB activation is a key modulator in driving chronic inflammation to cancer. HPV oncogene-mediated suppression of NF-kB activity contributes to HPV escape from the immune system. This review focuses on the diverse mechanisms of the virus immune evasion with HPV that leads to chronic inflammation and cancer.

scholarly journals Florida Crop/Pest Management Profile: Atemoya and Sugar Apple

EDIS ◽  
1969 ◽  
Vol 2002 (5) ◽  
Author(s):  
Mark A. Mossler ◽  
Olaf Norman Nesheim
Keyword(s):  
Pest Management ◽  
Cooperative Extension ◽  
Cooperative Extension Service ◽  
Human Nutrition ◽  
Extension Service ◽  
Food Science ◽  
University Of Florida ◽  
Crop Pest ◽  
Agricultural Sciences

This document is CIR 417 one of a series of the Pesticide Information Office, Food Science and Human Nutrition Department, Florida Cooperative Extension Service, Institute of Food and Agricultural Sciences, University of Florida. Published: September 2002.

scholarly journals Effect of Combination Therapy with Atorvastatin and Ursodeoxycholic Acid on the Course of Ischemic Heart Disease with Co-Existent Non-Alcoholic Fatty Liver Disease and Obesity

2016 ◽  
Vol 23 (4) ◽  
pp. 2016420
Author(s):  
Nataliya Karpyshyn
Keyword(s):  
Heart Disease ◽  
Liver Disease ◽  
Ischemic Heart Disease ◽  
Fatty Liver ◽  
Ursodeoxycholic Acid ◽  
Functional Status ◽  
Fatty Liver Disease ◽  
Ischemic Heart ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is considered as an independent predictor of cardiovascular diseases which plays an important role in the development of ischemic heart disease. The drug most frequently used for treating this comorbidity is atorvastatin which favours better survival outcomes and is essential in the primary and secondary prevention of cardiovascular diseases. Ursodeoxycholic acid is prescribed as an alternative therapy for ischemic heart disease with co-existent non-alcoholic fatty liver disease and obesity to eliminate statin side effects. The use of ursodeoxycholic acid as a hepatoprotector in comprehensive basic treatment contributes to the improvement of the cardiovascular system in patients with ischemic heart disease as well as the increase in treatment efficacy; it improves the functional status of the liver affecting the major pathogenic mechanisms of the disease.The objective of the research was to study the effect of combined hypolipidemic therapy with atorvastatin and ursodeoxycholic acid on the indices of blood lipids, liver transaminase levels, functional status of the liver and the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and obesity.Materials and methods. 20 patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity were examined. They received ursodeoxycholic acid in addition to atorvastatin for four weeks. All the patients underwent clinical tests, visceral ultrasonography, blood lipid test, liver transaminase test and 13C-methacetin breath test.Results. The study revealed a significant decrease in the level of the pro-atherogenic fractions of blood lipids (р<0.01) as well as an improved functional status of the liver due to a significant increase in metabolic capacity of the liver and cumulative dose on the 40th and 120th minutes after ursodeoxycholic acid administration (р<0.01).Conclusions. The use of ursodeoxycholic acid in addition to atorvastatin in patients with ischemic heart disease, co-existent non-alcoholic fatty liver disease and obesity makes it possible to avoid the adverse effect of hypolipidemic therapy on the functional status of the liver.

Sign in / Sign up

Export Citation Format

Share Document